EBV specific CTL: A model for immune therapy

Cliona M. Rooney, H. E. Heslop, M. K. Brenner

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


We have been generating Epstein-Barr virus specific cytotoxic T cells for patients at high risk of developing EBV driven lymphoma. To discover the fate of the cells in vivo, we first marked them genetically, using a retroviral vector. Our results in 51 patients show that the approach is safe, that the CTL persist for several years and that they are able to mediate anti-viral and anti-tumor effects. We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value.

Original languageEnglish (US)
Pages (from-to)497-498
Number of pages2
JournalVox Sanguinis
Issue numberSUPPL. 2
StatePublished - 1998

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'EBV specific CTL: A model for immune therapy'. Together they form a unique fingerprint.

Cite this